NAL-NL3 was presented at the FIA Congress in Italy, a respected international forum for hearing care professionals and industry leaders. The session attracted strong engagement, with attendees showing considerable interest in the scientific foundation and clinical value of the new prescription. The presentation was well received, with positive feedback highlighting NAL-NL3 as an important step forward in supporting improved hearing outcomes.